People don’t come to work every day to make money for shareholders, observes Vir Biotechnology president and CEO George Scangos. In biotech, he finds, most teams are instead motivated by the prospect of improving peoples’ lives. Consequently, he argues, his role as CEO is not to focus exclusively on maximizing shareholder returns, but to also think about responsibilities to other stakeholders, including patients, employees, the community and the environment.